← Back to Search

Radiation

Treatment (MRI-guided IMRT, ADT) for Prostate Adenocarcinoma

Phase 2

Waitlist Available

Led By Adam Mueller, MD

Research Sponsored by Thomas Jefferson University

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Be older than 18 years old

Timeline

Screening 3 weeks

Treatment Varies

Follow Up at 1 year

Awards & highlights

Study Summary

This trial tests if a shorter, higher dose radiation therapy for prostate cancer can reduce side effects and treatment time.

Eligible Conditions

Prostate Adenocarcinoma
Prostate Cancer

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ at 1 year

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~at 1 year

This trial's timeline: 3 weeks for screening, Varies for treatment, and at 1 year for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.

Primary outcome measures

Rate of late grade 2+ genitourinary (GU) toxicity

Secondary outcome measures

Biochemical failure

Incidence of acute GU and gastrointestinal (GI) toxicity

Incidence of late GI toxicity

+3 more

Trial Design

1Treatment groups

Experimental Treatment

Group I: Treatment (MRI-guided IMRT, ADT)Experimental Treatment8 Interventions

Patients undergo MRI-guided IMRT on study and receive SOC ADT throughout the trial. Patients may also undergo PSMA PET, CT, MRI, and bone scans at screening and undergo collection of blood samples throughout the trial.

Treatment

First Studied

Drug Approval Stage

How many patients have taken this drug

Magnetic Resonance Imaging

2017

Completed Phase 3

~1190

Biospecimen Collection

2004

Completed Phase 2

~1730

Antiandrogen Therapy

2015

Completed Phase 1

~10

PSMA PET Scan

2020

N/A

~10

Computed Tomography

2017

Completed Phase 2

~2720

Do I qualify?Apply below to find out

Find a Location

Who is running the clinical trial?

Thomas Jefferson UniversityLead Sponsor

445 Previous Clinical Trials

145,626 Total Patients Enrolled

Adam Mueller, MDPrincipal InvestigatorThomas Jefferson University

2 Previous Clinical Trials

3 Total Patients Enrolled

Media Library

MRI-guided Intensity-Modulated Radiation Therapy (Radiation) Clinical Trial Eligibility Overview. Trial Name: NCT05676463 — Phase 2

Prostate Adenocarcinoma Research Study Groups: Treatment (MRI-guided IMRT, ADT)

Prostate Adenocarcinoma Clinical Trial 2023: MRI-guided Intensity-Modulated Radiation Therapy Highlights & Side Effects. Trial Name: NCT05676463 — Phase 2

MRI-guided Intensity-Modulated Radiation Therapy (Radiation) 2023 Treatment Timeline for Medical Study. Trial Name: NCT05676463 — Phase 2

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Are there any remaining slots for participants in this test?

"Per the information accessible on clinicaltrials.gov, this research endeavour is currently accepting patient participants. As of 1/4/2023, it has been updated since its initial launch in November 16th 2022."

Answered by AI

Has the FDA sanctioned MRI-guided IMRT and ADT as a treatment protocol?

"The safety of this particular treatment, which involves MRI-guided IMRT and ADT, was rated a 2 on the Power team's scale. This determination is based on Phase 2 data showing some level of security while efficacy has yet to be established."

Answered by AI

How many individuals are being monitored in this medical research project?

"Affirmative. The clinical trial's information available on clinicialtrials.gov confirms this is an active study, which was initially posted on November 16th 2022 and recently amended on January 4th 2023. 88 participants are being admitted from one single medical centre."

Answered by AI

Recent research and studies

clinicaltrials.govStudy

MRI Guided Radiation Therapy for the Treatment of High Risk Prostate Cancer

2022. "MRI Guided Radiation Therapy for the Treatment of High Risk Prostate Cancer". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT05676463.